appeared in the *Economic Times* on 27th January, 1989, under the heading of DPCO impact favourable;

(b) if so, what are the basis on which the control measured and how Chairman BICP have come to the conclusion that under DPCO, 1987, the span of price control has been reduced from 77 per cent to 73 per cent;

(c) what are the basis and details of data on which he drew the conclusion that price control has become less cumbersome and at the same time more effective;

(d) whether it is a fact that the methodology of price control remains the same and producer has to sell out more to sell his product *vis-a-vis* small scale; and

(e) whether it is a fact that the worst sufferer is the consumer?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) The required details, to the extent available, will be collected and laid on the Table of the House.

(c) It was made in the context of reduction in the number of drugs under DPCO, 1987 from DPCO, 1979.

(d) The number of categories under control have been reduced from 3 to 2 improving the methodology.

(e) No, Sir.

Drugs and Formulations for Whole-sale Index

620 CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to state:

(a) what are the names of the bulk drugs and formulations in the basket of wholesale price index and when were they included;

(b) whether there is any proposal to review the basket and by when the basket would be reviewed;

(c) what was the wholesale price index of bulk drugs and formulations as in August, 1987, December, 1987 and December, 1988; and

(d) what is the weightage assigned to each bulk drug and formulations for the purpose of compiling the index?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (d) The required details to the extent available, will be collected and laid on the Table of the House.

Concentration of Formulation Market

621. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to state:

(a) whether the criterion of very high concentration of formulation market is a new criterion evolved by the Kelkar Committee;

(b) whether it is a fact that this criterion was not used in the initial report;

(c) if so, how drugs like Triprolidine, Polymixin B Sulphate, Flucinolone, Nandrolone Phenyl Propionate and Nandrolone Decanoate were omitted from the list proposed for price control;

(d) what is the percentage control in the market share that has been kept in view to determine the degree of concentration; and

(e) what are the names of drugs recommended for price control based on new criteria in the supplementary report?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The required details, to the extent available, will be collected and laid on the Table of the House.

Filling wrong affidavits about Baralgon Ketone

622 SHRI ALADI ARUNA *alias* V. ARUNACHALAM. Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 239 given in

the Rajya Sabha on the 28th November, 1988 and state:

(a) whether Government's attention was drawn to the judgement of the Supreme Court in the matter of drugs;

(b) whether it is a fact that Supreme Court has noticed that M/s. Hoechst are enjoying a price of Rs. 24735.38 per kg. in respect of Baralgon Ketone in the formulation;

(c) whether it is a fact that this figure is also given in the affidavits filed before the High Court and the Supreme Court;

(d) whether it is a fact that for the purpose of recovery, a figure of Rs. 8019 per Kg. has now been used;

(e) if so, what action has been taken against the officers who filed wrong affidavits before the Courts; and

(f) whether it is a fact that crores of rupees have been swindled in the matter by distorting the facts?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) The required details to the extent information is available would be collected and laid on the Table of the House.

Assessment of overcharged amounts for recovery from Companies

623 SHRI ALADI ARUNA *alias* V. ARUNACHALAM: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 239 given in the Rajya Sabha on the 28th November, 1988 and state:

(a) what is the overcharged amount assessed by the special team against each company covered by the Supreme Court judgement;

(b) how much amount each company has paid so far; what is the balance due from each company and from which date the balance is due;

(c) what are the main reasons for delay in the recovery of the amount; and

(d) on what basis the producers are keeping the Government money with them and whether during 1988 or 1987, any letter was issued to the companies to deposit the balance amount with the Government?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The details of the amount assessed by the special team for the period upto 31.12.83 and the amounts paid by the companies are given in the Annexure. [*See* Appendix CXLIX, Annexure No. 26]

(c) and (d) Since the prices of drugs had not been revised since 1980, a decision was taken to give to hearing to the companies concerned on their price revision application for prices after 31st December, 1983.

DPEA dues worked out by Special Team

624. SHRI ALADI ARUNA *alias* V. ARUNACHALAM: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 239 given in the Rajya Sabha on the 28th November, 1988 and state:

(a) whether it is a fact that the special team has already submitted its report in respect of the amount due from other companies covered by the Supreme Court judgement;

(b) if so, what is the amount worked out by the special team against each company; and

(c) how much amount each company has so far paid into the Drug Price Equalisation Account?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The Committee has not submitted its report in respect of all the other companies.

(b) and (c) Do not arise.

राजस्थान में एस० टी० डी० सुविधा

625. **डा० अबरार अहमद खान:** क्या संचार मंत्री यह बताने की कृपा करेंगे कि राजस्थान में सभी जिलों को एस० टी० डी० सुविधा से कब तक जोड़ दिए जाने की संभावना है?